Biologics for Autoimmune Diseases
Engineering Next Generation Modalities for Durable Treatments
5/10/2027 - May 11, 2027 ALL TIMES EDT
For 2027, The PEGS Biologics for Autoimmune Diseases conference explores the engineering work driving the field toward durable, mechanism-specific treatment rather than lifelong management. Talks span cellular therapies designed to reset a dysregulated immune system, tolerance-inducing approaches that retrain rather than deplete, and next-generation antibody architectures capable of hitting multiple targets or pathways at once. In vivo delivery platforms, complement-targeted biologics, and donor-derived cell engineering address how these therapies reach patients affordably and safely. We will consider diseases still lacking adequate treatment options, including myasthenia gravis, IBD, and celiac disease, and examine how AI and large-scale biological data are impacting target discovery.
Preliminary Agenda

PLENARY KEYNOTE SESSION

Is AI-Driven Antibody Discovery a Data-Driven Sport?

Photo of Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC) , Prof Structural Bioinformatics , Statistics , Oxford University
Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC) , Prof Structural Bioinformatics , Statistics , Oxford University

YOUNG SCIENTIST KEYNOTE

Generative Design of Evolution-Resilient Antiviral Biologics

Photo of Pranam Chatterjee, PhD, Assistant Professor, Bioengineering and Computer Science, University of Pennsylvania , Assistant Professor , Bioengineering and Computer Science , University of Pennsylvania
Pranam Chatterjee, PhD, Assistant Professor, Bioengineering and Computer Science, University of Pennsylvania , Assistant Professor , Bioengineering and Computer Science , University of Pennsylvania

Viral evolution can erode the activity of antiviral therapeutics. We integrate evolutionary forecasting with generative molecular design to develop peptides and proteins that remain effective against plausible future variants. Tree-valued Schrödinger bridge matching (TreeSBM) predicts branching evolutionary trajectories and their uncertainty. PROPHET, our multi-objective discrete flow model, then uses these forecasts to generate and optimize biologics for target engagement, therapeutic properties, and robustness across predicted futures. I will present unpublished pseudoviral infection data demonstrating functional envelope variants predicted by TreeSBM and PROPHET-designed peptides that block infection by later variants of concern and interest, using only earlier viral sequences for design.

ENGINEERING ANTIGEN-SPECIFIC TOLERANCE

mRNA-Delivered Tolerizing Therapies for Autoimmunity

Photo of Dave Easterhoff, PhD, Director, Platform Immunology and Research & Innovation, Moderna , Director , Platform Immunology and Research & Innovation , Moderna
Dave Easterhoff, PhD, Director, Platform Immunology and Research & Innovation, Moderna , Director , Platform Immunology and Research & Innovation , Moderna

mRNA lipid nanoparticles (mRNA/LNPs) offer a programmable strategy for antigen-specific immune tolerance. MOG-encoding mRNA/LNPs expanded antigen-specific CD4? T cells with preferential regulatory T cell differentiation in mice and non-human primates and prevented or stabilized EAE. Mechanistically, regulatory versus effector outcomes were shaped by the encoded antigen and the thymically shaped T cell repertoire rather than by LNP delivery alone. Co-delivery of an IL-2 mutein redirected responses to foreign antigens toward a regulatory phenotype, highlighting the platform’s potential for modular, antigen-specific immune reprogramming.

Engineering Antigen-Specific Tolerance: Biological Lessons from Tolerogenic Immunotherapies Modulating MHC Class II Autoimmunity

Photo of Adel ElSohly, PhD, Group Leader, Protein Chemistry, Genentech, Inc. , Principal Scientist , Protein Chemistry , Genentech Inc
Adel ElSohly, PhD, Group Leader, Protein Chemistry, Genentech, Inc. , Principal Scientist , Protein Chemistry , Genentech Inc

Antigen-specific therapies aimed at treating autoimmune diseases is a burgeoning field of drug discovery. As a number of autoimmune diseases are genetically associated with MHC-class II alleles, understanding the role of antigen presentation and subsequent T cell reactivity is paramount to engineering effective therapeutics. Here, we describe our efforts to understand biological mechanisms of antigen-specific tolerance in the context of tolerogenic mRNA vaccines.

KEYNOTE PRESENTATION: Building Better Tregs: CAR Engineering, Treg Biology, and AI-Driven CAR Treg Design

Photo of Leonardo M. R. Ferreira, PhD, Assistant Professor, Pharmacology and Immunology, Medical University of South Carolina , Assistant Professor , Pharmacology & Immunology , Medical University of South Carolina
Leonardo M. R. Ferreira, PhD, Assistant Professor, Pharmacology and Immunology, Medical University of South Carolina , Assistant Professor , Pharmacology & Immunology , Medical University of South Carolina

DEPLETING AND REDIRECTING EFFECTOR CELLS

Who to Deplete, How Deeply, and When: Lessons from Rituximab for Next-Generation B Cell Therapies in SLE

Photo of Fareeha Tariq, PhD, Postdoctoral Research Associate, Rheumatology, King's College London , Postdoctoral Research Associate , Rheumatology , King's College London
Fareeha Tariq, PhD, Postdoctoral Research Associate, Rheumatology, King's College London , Postdoctoral Research Associate , Rheumatology , King's College London

Rituximab established the therapeutic principle of B cell depletion in SLE, yet its randomized trials missed their primary endpoints and clinical responses remain difficult to predict. Two decades of use have clarified the underlying constraints. Peripheral depletion is an imperfect surrogate for clearance from tissue and lymphoid compartments, long-lived plasma cells persist, BAFF rises following depletion, and anti-drug antibodies contribute to secondary loss of response. This presentation revisits these lessons to address three questions for next-generation therapies, namely which patients should be treated, how deeply the relevant compartments must be cleared, and when intervention should occur.

Discovery, Characterization, and Pre-Clinical Pharmacology of S-6204, an IgE Dissociator Antibody for Treatment of Allergic and Atopic Diseases

Photo of Jyothsna Visweswaraiah, PhD, Vice President, Drug Creation, Seismic Therapeutic , Vice President , Drug Creation , Seismic Therapeutic
Jyothsna Visweswaraiah, PhD, Vice President, Drug Creation, Seismic Therapeutic , Vice President , Drug Creation , Seismic Therapeutic

NEXT-GENERATION BISPECIFICS AND PROXIMITY ENGAGERS

XmAb148, an IL-13 x IL-31RA Bispecific Antibody for Atopic Dermatitis: Model-Guided Selection of Receptor versus Cytokine Targeting

Photo of Matthew J. Bernett, PhD, Executive Director, Protein & Antibody Engineering, Xencor , Sr Dir Protein Engineering , Protein Engineering , Xencor Inc
Matthew J. Bernett, PhD, Executive Director, Protein & Antibody Engineering, Xencor , Sr Dir Protein Engineering , Protein Engineering , Xencor Inc

A key design choice for bispecific antibodies that block cytokine signaling is whether to target the cytokine or its receptor. We addressed this for IL-13 and IL-31, which drive inflammation and itch in atopic dermatitis, using mechanistic modeling of cytokine abundance and turnover. This guided the design of XmAb148, a native IgG-like IL-13 x IL-31RA bispecific with extended half-life that potently inhibits both pathways in vitro.

Bispecific Antibody Discovery at Surfaceome Scale

Photo of Greg Lazar, PhD, Chief Scientific Officer, Dualitas Therapeutics , Chief Scientific Officer , Dualitas Therapeutics
Greg Lazar, PhD, Chief Scientific Officer, Dualitas Therapeutics , Chief Scientific Officer , Dualitas Therapeutics

Approaches to bispecific discovery have thus far been narrowly focused on pre-determined target pairs of known biology to often realize incremental gains. Dualitas has built a bispecific discovery engine that operates at combinatorial scale, enabling functional screening of cell surfaceomes at vast target and epitope space. Large unbiased screens have illuminated novel co-target biology and yielded an emerging bispecific pipeline of I&I programs with differentiated activities unachievable by conventional inhibitors. Moreover, observations of repeatable activities are elucidating a novel collection of immune engagers, plug-and-playable mechanisms and antibody arms that can bring superior pharmacology to established therapeutic pathways.

ENGINEERING APPROACHES FOR HIGH-UNMET-NEED AUTOIMMUNE INDICATIONS

Selective CD16A Blockade for Immune Thrombocytopenia and Autoimmune Hemolytic Anemia

Photo of Pierre Bruhns, PhD, Principal Investigator & Research Director, Antibodies in Therapy & Pathology Lab, Institut Pasteur , Principal Investigator & Research Dir , Antibodies in Therapy & Pathology Lab , Institut Pasteur
Pierre Bruhns, PhD, Principal Investigator & Research Director, Antibodies in Therapy & Pathology Lab, Institut Pasteur , Principal Investigator & Research Dir , Antibodies in Therapy & Pathology Lab , Institut Pasteur

Among human IgG receptors (FcgR), FcgRIIIA/CD16A expressed by macrophages and NK cells primarily, represents a therapeutic target in autoimmunity. Indeed, CD16A may be the prime receptor responsible for cell depletion/phagocytosis in autoimmune diseases in which IgG autoantibodies opsonize platelets (immune thrombocytopenic purpura: ITP) or red blood cells (Autoimmune hemolytic anemia: AIHA), for example. A novel, Fc-silent, antagonistic blocking mAb to CD16 binds with nanomolar affinity to a CD16 epitope overlapping the IgG binding region. In Fc-receptor humanized mice, 3G4 leads to fast remissions of chronic AIHA and ITP, without adverse reactions at high or repeated doses (patent: US12698331B2).

A First-in-Class Enzyme Based Trispecific Immunotherapy for Multiple Sclerosis

Photo of George Kopsidas, PhD, Founder and Chief Scientific Officer, Imunexus Therapeutics , Exec Dir & CSO & Founder , Imunexus
George Kopsidas, PhD, Founder and Chief Scientific Officer, Imunexus Therapeutics , Exec Dir & CSO & Founder , Imunexus

Targeting Insulin Neoepitopes in Type 1 Diabetes

Photo of Rocky Strollo, MD, PhD, Associate Professor, Endocrinology, San Raffaele University of Rome , Associate Professor , San Raffaele University of Rome
Rocky Strollo, MD, PhD, Associate Professor, Endocrinology, San Raffaele University of Rome , Associate Professor , San Raffaele University of Rome

ENGINEERING THE COMPLEMENT SYSTEM

Drug Design Inspired by in situ Structural Immunology

Photo of Thomas Sharp, PhD, Associate Professor, Biochemistry, University of Bristol , Professor , Structural and Synthetic Immunology , University Of Bristol
Thomas Sharp, PhD, Associate Professor, Biochemistry, University of Bristol , Professor , Structural and Synthetic Immunology , University Of Bristol

Using in situ structural biology, we investigate the molecular steps underlying antibody-mediated complement activation. These insights enable rational design of next-generation immunotherapies. By integrating structure-guided drug design with AI-driven approaches, we are exploring new strategies to modulate complement. Finally, I will highlight how correlative cryogenic super-resolution microscopy and cryoET enable the localization and structural analysis of molecular complexes within cells, opening new opportunities to study immune function directly in cellular environments.

Long Lasting Neutralization of C1s by Optimized pH-Dependent Recycling Antibody

Photo of Noriyuki Takahashi, Director, Research Head, Chugai Pharmabody Research Pte Ltd. , Research Head , Research Division , Chugai Pharmabody Research Pte Ltd
Noriyuki Takahashi, Director, Research Head, Chugai Pharmabody Research Pte Ltd. , Research Head , Research Division , Chugai Pharmabody Research Pte Ltd

Aberrant activation of the complement system and its pathways has been implicated in multiple diseases. However, therapeutic blockade with antibody drugs often requires high doses and frequent administration because the target antigen is abundant in patient plasma and undergoes rapid turnover. To overcome these challenges and provide an improved treatment option, RAY121, a novel anti-C1s antibody, was developed. RAY121 neutralizes the classical complement pathway and achieves an extended half-life through Chugai’s proprietary pH-dependent antigen-binding technology, SMART-Ig. This presentation describes the lead identification and antibody engineering strategies employed during preclinical development and discusses the unique characteristics of RAY121 in detail.


For more details on the conference, please contact:
Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-329-2964
Email: ksimmons@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-1340
Email: ashleyparsons@healthtech.com


Register

View By:


Premier Sponsors

Biointron_new       Kactus